Algorae Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LVCLF research report →
Price Chart
About the company
Algorae Pharmaceuticals Limited, established in 1987 and based in Melbourne, Australia, is a pharmaceutical development company. The firm primarily conducts its research and development in New Zealand, focusing on living cell technologies. Its product pipeline includes several key candidates: AI-116, a novel combination therapy featuring cannabidiol and an existing pharmaceutical ingredient, intended for the treatment of dementia, including Alzheimer's disease; NTCELL, an alginate-coated capsule developed to address Parkinson's disease; and AI-168, another combination drug that combines a cannabinoid with an off-patent pharmaceutical ingredient, aimed at treating cardiovascular conditions like hypertension.
- CEO
- David Richard Hainsworth
- IPO
- 2010
- Employees
- 48
- HQ
- Melbourne, VI, AU
Get TickerSpark's AI analysis on LVCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.36M
- P/E
- -5.00
- PEG
- 0.06
- P/S
- 0.00
- P/B
- 3.84
- EV/EBITDA
- -4.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -132.20%
- ROIC
- -105.43%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,255,522
- Net Income
- $-2,809,313-249.9%
- EPS
- $-0.00-200.0%
- OCF Growth
- -343675.5%
- FCF Growth
- -343675.2%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.03
- RSI (14)
- 72
- Avg Volume
- 3.93K
No earnings-call transcripts are available for LVCLF yet.
- Free Float
- 99.1%
- Shares Outstanding
- 2.03B
- Float Shares
- 2.01B
Our LVCLF coverage
Recent articles, reports, and earnings notes.
No research on LVCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LVCLF report →Could quantum computing advances sink Bitcoin?
proactiveinvestors.com · May 18
Algorae completes AI prediction phase for expanded drug combination program
proactiveinvestors.com · May 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.